Billiontoone Inc (BLLN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$99.39-0.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Intact: The reason to own it still holds.
BillionToOne aims to grow revenue to about $465M in 2026. This is a 48% to 52% increase from 2025. The company beat earnings recently and raised guidance. It has a strong position in molecular diagnostics.
Growth may slow if revenue falls below $450M in 2026. High valuation risks a correction. The company is still loss-making and must prove sustained profits.
The market expects about 38% revenue growth next year. Our fair value near $16.57 matches this view. We see upside if BillionToOne hits its higher $465M revenue target.
Breaks if: Material financial obligations impair growth or liquidity
Breaks if: EPS falls below $0.80 in FY26
revenue falls below $450M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
BLLN represents a durable compounder in the healthcare sector. The current thesis state is intact, with management focused on revenue growth and profitability, but the valuation is considered expensive compared to peers.
The market appears to have priced in a high level of expectations, reflected in an expensive valuation. There is a notable expectations gap, indicating that investors may be anticipating continued strong performance.
Management has shown a commitment to increasing revenue guidance and maintaining profitability, with recent financial performance indicating strong growth. However, there is a mixed outlook on achieving consistent profitability and expanding product offerings.
The thesis hinges on management's ability to meet or exceed revenue guidance and maintain profitability. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue growing revenue with full year 2026 guidance reiterated at $450 million to $465 million, representing 48% to 52% growth over 2025.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $83.5 million in 2025-Q3 to $108.4 million in 2026-Q1 and $109.4 million in 2026-Q2. Management reiterated 2026 full year revenue guidance at $450 million to $465 million, representing 48% to 52% growth over 2025. The trajectory is delivering consistent revenue growth and guidance upgrades.
“Reiterating 2026 full year revenue guidance to be in a range of $450 million to $465 million, which represents 48% to 52% growth over 2025.”
“Raising 2026 full year revenue guidance to be in a range of $450 million to $465 million, which represents 48% to 52% growth over 2025.”
“BillionToOne now expects full year 2026 total revenue of $430 million to $445 million, representing growth of 41% to 46% compared to full year 2025.”
Over the next 1 to 3 years, BLLN's performance will depend on management execution and external market conditions. Not investment advice.